Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Intestinal Motility Disorders Treatment & Management

  • Author: Nafisa K Kuwajerwala, MD; Chief Editor: Julian Katz, MD  more...
 
Updated: Dec 29, 2015
 

Approach Considerations

Because several different drugs can cause intestinal motility disorders, avoiding them, if possible, may resolve the condition. In selected patients, pharmacotherapy may be helpful. Gastric preprandial dysrhythmia may lead to impaired gastric emptying, thus contributing to irregular absorption of drugs from the small intestine and conducing to disabling response fluctuations of the therapy.

Cognitive interventions (eg, cognitive behavorial therapy, hypnotherapy) have been successful in managing abdominal pain in patients with irritable bowel syndrome; however, they have limited utility for routine use in daily practice owing to their labor intensiveness and tight availability.[20]

Surgery is not usually performed to treat patients with primary intestinal motility disorders, except in the treatment of idiopathic constipation that does not respond to medical therapies and in the treatment of intestinal pseudo-obstruction. Surgery for these patients is always palliative. Only patients who are incapacitated by their symptoms or those whose nutritional status is adversely affected undergo surgery.

Neural stem cell transplantation may be beneficial for patients with intestinal motility disorders associated with enteric neuropathy.[21] A murine study demonstrated that transplanted enteric neural progenitor cells could generate functional enteric neurons in the postnatal bowel.[21]

Patients with intestinal motility disorders must be educated in ways of coping with their condition and instructed to avoid any situation or substance that may cause the symptoms to worsen. Psychological counseling may be helpful.

Next

Pharmacologic Therapy

Avoidance of drugs that can cause intestinal motility disorders is recommended if doing so is feasible. In patients with primitive (idiopathic) intestinal motility disorders, the administration of some drugs may be useful to control symptoms.

Drugs used in the management of intestinal motility disorders include parasympathomimetics, prokinetic agents, opioid antagonists, antidiarrheals, and antibiotics. The agents that are most useful in the treatment of these disorders are neostigmine, bethanechol, metoclopramide, cisapride, and loperamide.[22, 23, 24, 25] Prucalopride appears promising for the treatment of chronic constipation[26] ; its low side-effect and drug-interaction profile appear to allow it to be a safe option in elderly patients with chronic constipation.[27]  

Tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) provide symptomatic relief, but this has been demonstrated only for TCAs in meta-analyses.[20]

The use of injectable bulking treatment appears to be effective and safe in the long-term management of fecal incontinence.[28]  In one study, symptomatic reduction with non-animal stabilized hyaluronic acid/dextranomer (NASHA Dx) occurred in 52% of 136 patients at 6 months, with sustained results at 12 months (57%) and at 36 months (52%). Mean change from baseline Cleveland Clinic Florida Fecal Incontinence Score (CCFIS) and Fecal Incontinence Quality of Life Scale (FIQL) scores improved between baseline and at 36-month follow-up.[28]

Broad-spectrum antibiotics (not discussed in detail in this topic) may be needed to treat stagnant loop syndrome with bacterial colonization. A 7-day course of antibiotics (eg, tetracycline, doxycycline, ampicillin, quinolones, metronidazole) may lead to remission of the diarrhea.[29]

Previous
Next

Endoscopy, Ostomy, and Bowel Resection

Before the decision is made to perform a particular operation, it is extremely important to determine which symptoms are being palliated and from which area of the intestine these symptoms emanate. Surgery is always indicated if the patient has complications such as perforation of the bowel or peritonitis.

In patients with acute intestinal pseudo-obstruction, endoscopic decompression is suitable and may resolve the problem. When indicated, endoscopic decompression should always be attempted before any open surgical intervention. Some patients may benefit from laparoscopy and lysis of adhesions. Surgical procedures such as feeding jejunostomies, decompressive gastrostomy, or ileostomy also may be necessary.

Transplantation of the small intestine is still in the experimental stages, but steady progress has been made, and improved survival is being reported.[30, 31]

Patients with chronic intestinal motility disorders may experience symptom relief after total colectomy in conjunction with near-total proctectomy. This surgical procedure is successful in nearly 90% of patients. Some surgeons prefer to perform a total proctocolectomy with ileoanal anastomosis on a J-pouch.

This procedure may be necessary in patients who have a megacolon and severe abdominal distention. However, even with such treatment, some patients continue to have severe symptoms from coexisting disease of the small intestine. In addition, colectomy may exacerbate diarrhea. Accordingly, palliative surgery should be undertaken only after careful consideration; unnecessary surgery must be avoided at all costs.

After any abdominal procedure, exclusion of mechanical obstruction caused by adhesions may be difficult if the patient returns with symptoms of intestinal obstruction. On the other hand, surgery may be necessary for acute problems, such as intestinal volvulus, perforation, or herniation, all of which can occur in patients with pseudo-obstruction.

Extensive, sometimes radical, small-bowel resection may be necessary in rare cases of unrelenting intestinal obstruction and massive intestinal fluid secretion that make it impossible to keep up with fluid losses or control severe obstructive symptoms. Some patients continue to have abdominal pain or such copious intestinal secretion that vomiting and fluid and electrolyte losses remain substantial. They may require a decompressive enterostomy or an extended small-bowel resection; in such cases, they are invariably on home parenteral nutrition.

If the patient is unable to maintain adequate nutritional intake or continues to have severe symptoms despite palliative treatment, long-term home parenteral nutrition may be necessary. Many patients who are on home parenteral nutrition seem to do well, though some develop sepsis and thrombotic complications of the central intravenous catheter, depression, prolonged suffering, and analgesic dependence.

Support groups, such as the American Association of Gastrointestinal Motility Disorders and the American Pseudo-Obstruction and Hirschsprung Society, provide advice, information, educational meetings, and psychological support to patients and their families.

Previous
Next

Diet and Activity

Changes in dietary habits alone can help cure motility disorders. Correct fiber intake is useful in patients with either constipation or stool leakage. Fiber and water must be abundant in the diet of patients with constipation; fermentable foods should be avoided. Patients should take small frequent meals (6-8 times a day), avoid foods high in fat or lactose, and avoid residue- and gas-producing foods.[20] Pureed foods (via a blender or other means) may be tolerated by some individuals.

Patients can receive supplementation with liquid formulations, vitamins, and minerals (eg, vitamin B-12, iron, calcium, folic acid, water-soluble vitamins, vitamin A, vitamin D, vitamin E, vitamin K, trace elements) as needed to meet the requirements. Consultation with a dietitian helps provide the patient with a number of options.

Mild physical exercise is not contraindicated and may be very useful for symptom relief in patients with irritable bowel syndrome or constipation.

Previous
Next

Prevention

A healthy lifestyle is the best prevention for intestinal motility disorders. A diet rich in fiber, especially insoluble fibers, cannot prevent colon cancer, but it may prevent constipation and impaction, its more severe complication. In addition, because insoluble fibers create a mass effect in the stomach, they may be helpful in weight control, preventing diseases related to obesity (eg, cardiovascular accidents and endocrine disturbances).

Prescriptions of laxatives, diuretics, benzodiazepines, and anticholinergic drugs should be limited. Such agents may interfere with gastrointestinal motility; they should be administered only if they are clearly useful for patients, and only for a limited time.

Any patients older than 50 years should be scheduled for colonoscopy, even if they are not symptomatic.

Patients with a history of abdominal surgery who have recurrent bowel habit disorders should be carefully evaluated with an eye to detecting eventual adhesions. The same consideration is valid for patients with a history of radiotherapy of the abdomen or pelvis.

Previous
 
 
Contributor Information and Disclosures
Author

Nafisa K Kuwajerwala, MD Staff Surgeon, Breast Care Center, William Beaumont Hospital

Nafisa K Kuwajerwala, MD is a member of the following medical societies: American College of Surgeons, American Society of Breast Surgeons, American Society of Breast Disease

Disclosure: Nothing to disclose.

Coauthor(s)

Vivek V Gumaste, MD Associate Professor of Medicine, Mount Sinai School of Medicine of New York University; Adjunct Clinical Assistant, Mount Sinai Hospital; Director, Division of Gastroenterology, City Hospital Center at Elmhurst; Program Director of GI Fellowship (Independent Program); Regional Director of Gastroenterology, Queens Health Network

Vivek V Gumaste, MD is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association

Disclosure: Nothing to disclose.

Luigi Santacroce, MD Assistant Professor, Medical School, State University at Bari, Italy

Disclosure: Nothing to disclose.

Venkata Subramanian Kanthimathinathan, MD Fellow in Bariatric/Advanced Laparoscopic Surgery, University of Missouri Healthcare

Disclosure: Nothing to disclose.

Chief Editor

Julian Katz, MD Clinical Professor of Medicine, Drexel University College of Medicine

Julian Katz, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Geriatrics Society, American Medical Association, American Society for Gastrointestinal Endoscopy, American Society of Law, Medicine & Ethics, American Trauma Society, Association of American Medical Colleges, Physicians for Social Responsibility

Disclosure: Nothing to disclose.

Acknowledgements

Silvia Gagliardi, MD Consulting Staff, Department of Surgery, Medical Center Vita, Italy

Disclosure: Nothing to disclose.

Douglas M Heuman, MD, FACP, FACG, AGAF Chief of GI, Hepatology, and Nutrition at North Shore University Hospital/Long Island Jewish Medical Center; Professor, Department of Medicine, Hofstra North Shore-LIJ School of Medicine

Douglas M Heuman, MD, FACP, FACG, AGAF is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Physicians, and American Gastroenterological Association

Disclosure: Novartis Grant/research funds Other; Bayer Grant/research funds Other; Otsuka Grant/research funds None; Bristol Myers Squibb Grant/research funds Other; Scynexis None None; Salix Grant/research funds Other; MannKind Other

Sandeep Mukherjee, MB, BCh, MPH, FRCPC Associate Professor, Department of Internal Medicine, Section of Gastroenterology and Hepatology, University of Nebraska Medical Center; Consulting Staff, Section of Gastroenterology and Hepatology, Veteran Affairs Medical Center

Sandeep Mukherjee, MB, BCh, MPH, FRCPC is a member of the following medical societies: Royal College of Physicians and Surgeons of Canada

Disclosure: Merck Honoraria Speaking and teaching; Ikaria Pharmaceuticals Honoraria Board membership

Shivkumar Prabhu, MD Consulting Staff, Department of Internal Medicine, St John Detroit Riverview Hospital

Disclosure: Nothing to disclose.

Daniel Schafer Department of Surgery, University of Nebraska Medical Center

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. Di Lorenzo C, Youssef NN. Diagnosis and management of intestinal motility disorders. Semin Pediatr Surg. 2010 Feb. 19(1):50-8. [Medline].

  2. Keller J, Layer P. Intestinal and anorectal motility and functional disorders. Best Pract Res Clin Gastroenterol. 2009. 23(3):407-23. [Medline].

  3. Venkatasubramani N, Sood MR. Motility disorders of the gastrointestinal tract. Indian J Pediatr. 2006 Oct. 73(10):927-30. [Medline].

  4. Ouyang A, Locke GR 3rd. Overview of neurogastroenterology-gastrointestinal motility and functional GI disorders: classification, prevalence, and epidemiology. Gastroenterol Clin North Am. 2007 Sep. 36(3):485-98, vii. [Medline].

  5. Rao SS. Constipation: evaluation and treatment of colonic and anorectal motility disorders. Gastroenterol Clin North Am. 2007 Sep. 36(3):687-711, x. [Medline].

  6. De Giorgio R, Cogliandro RF, Barbara G, Corinaldesi R, Stanghellini V. Chronic intestinal pseudo-obstruction: clinical features, diagnosis, and therapy. Gastroenterol Clin North Am. 2011 Dec. 40(4):787-807. [Medline].

  7. Rudolph CD, Hyman PE, Altschuler SM, Christensen J, Colletti RB, Cucchiara S, et al. Diagnosis and treatment of chronic intestinal pseudo-obstruction in children: report of consensus workshop. J Pediatr Gastroenterol Nutr. 1997 Jan. 24(1):102-12. [Medline].

  8. Wouters MM, Vicario M, Santos J. The role of mast cells in functional GI disorders. Gut. 2016 Jan. 65 (1):155-68. [Medline].

  9. Knowles CH, Martin JE. Slow transit constipation: a model of human gut dysmotility. Review of possible aetiologies. Neurogastroenterol Motil. 2000 Apr. 12(2):181-96. [Medline].

  10. Amiot A, Tchikviladze M, Joly F, et al. Frequency of mitochondrial defects in patients with chronic intestinal pseudo-obstruction. Gastroenterology. 2009 Jul. 137(1):101-9. [Medline].

  11. Li B, Wang JR, Ma YL. Bowel sounds and monitoring gastrointestinal motility in critically ill patients. Clin Nurse Spec. 2012 Jan. 26(1):29-34. [Medline].

  12. Remes-Troche JM, Rao SS. Diagnostic testing in patients with chronic constipation. Curr Gastroenterol Rep. 2006 Oct. 8(5):416-24. [Medline].

  13. Maqbool S, Parkman HP, Friedenberg FK. Wireless capsule motility: comparison of the SmartPill GI monitoring system with scintigraphy for measuring whole gut transit. Dig Dis Sci. 2009 Oct. 54(10):2167-74. [Medline].

  14. [Guideline] American College of Radiology (ACR), the Society of Nuclear Medicine (SNM), and the Society for Pediatric Radiology (SPR). ACR–SNM–SPR Practice parameter for the performance of gastrointestinal scintigraphy. Res. 29 – 2010, Amended 2014 (Res. 39). ACR American College of Radiology. Available at http://www.acr.org/Quality-Safety/Standards-Guidelines/Practice-Guidelines-by-Modality/Nuclear-Medicine. Accessed: October 29, 2014.

  15. Alyami J, Spiller RC, Marciani L. Magnetic resonance imaging to evaluate gastrointestinal function. Neurogastroenterol Motil. 2015 Dec. 27 (12):1687-92. [Medline].

  16. Burns AJ. Disorders of interstitial cells of Cajal. J Pediatr Gastroenterol Nutr. 2007 Dec. 45 Suppl 2:S103-6. [Medline].

  17. He CL, Burgart L, Wang L, Pemberton J, Young-Fadok T, Szurszewski J, et al. Decreased interstitial cell of cajal volume in patients with slow-transit constipation. Gastroenterology. 2000 Jan. 118(1):14-21. [Medline].

  18. Pardi DS, Miller SM, Miller DL, Burgart LJ, Szurszewski JH, Lennon VA, et al. Paraneoplastic dysmotility: loss of interstitial cells of Cajal. Am J Gastroenterol. 2002 Jul. 97(7):1828-33. [Medline].

  19. Sanders KM. Interstitial cells of Cajal at the clinical and scientific interface. J Physiol. 2006 Nov 1. 576(Pt 3):683-7. [Medline].

  20. Vanuytsel T, Tack JF, Boeckxstaens GE. Treatment of abdominal pain in irritable bowel syndrome. J Gastroenterol. 2014 Aug. 49 (8):1193-205. [Medline].

  21. Hotta R, Stamp LA, Foong JP, McConnell SN, Bergner AJ, Anderson RB, et al. Transplanted progenitors generate functional enteric neurons in the postnatal colon. J Clin Invest. 2013 Mar 1. 123(3):1182-91. [Medline]. [Full Text].

  22. Cleveland Clinical Foundation, Center for Gastrointestinal Motility Disorders. Intestinal motility disorders. Available at: http://www.ccf.org/gastro/motility/default.htm. Cleveland, Ohio: Cleveland Clinic;. 1999. [Full Text].

  23. Fu A. Neostigmine: an alternative treatment for constipation. Dynamics. 2005. 16(1):13-5. [Medline].

  24. Karamanolis G, Tack J. Promotility medications--now and in the future. Dig Dis. 2006. 24(3-4):297-307. [Medline].

  25. Sarna SK. Molecular, functional, and pharmacological targets for the development of gut promotility drugs. Am J Physiol Gastrointest Liver Physiol. 2006 Oct. 291(4):G545-55. [Medline].

  26. Quigley EM. Prucalopride: safety, efficacy and potential applications. Therap Adv Gastroenterol. 2012 Jan. 5(1):23-30. [Medline]. [Full Text].

  27. Bassotti G, Gambaccini D, Bellini M. Prucalopride succinate for the treatment of chronic constipation: an update and future directions. Expert Rev Gastroenterol Hepatol. 2015 Dec 8. [Medline].

  28. Mellgren A, Matzel KE, Pollack J, et al.; for the Nasha Dx Study Group. Long-term efficacy of NASHA Dx injection therapy for treatment of fecal incontinence. Neurogastroenterol Motil. 2014 Aug. 26 (8):1087-94. [Medline].

  29. Mazzone A, Farrugia G. Evolving concepts in the cellular control of gastrointestinal motility: neurogastroenterology and enteric sciences. Gastroenterol Clin North Am. 2007 Sep. 36(3):499-513, vii. [Medline].

  30. Sigurdsson L, Reyes J, Kocoshis SA, et al. Intestinal transplantation in children with chronic intestinal pseudo- obstruction. Gut. 1999 Oct. 45(4):570-4. [Medline].

  31. Millar AJ, Gupte G, Sharif K. Intestinal transplantation for motility disorders. Semin Pediatr Surg. 2009 Nov. 18(4):258-62. [Medline].

  32. Parthasarathy G, Ravi K, Camilleri M, Andrews C, et al. Effect of neostigmine on gastroduodenal motility in patients with suspected gastrointestinal motility disorders. Neurogastroenterol Motil. 2015 Dec. 27 (12):1736-46. [Medline].

  33. Menys A, Butt S, Emmanuel A, et al. Comparative quantitative assessment of global small bowel motility using magnetic resonance imaging in chronic intestinal pseudo-obstruction and healthy controls. Neurogastroenterol Motil. 2015 Dec 10. [Medline].

 
Previous
Next
 
Dilated cecum (16 cm) and colon in patient with pseudocolonic obstruction.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.